NCT07075016
Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT07075016 |
| Title | Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy (EVOLVE 1) |
| Acronym | EVOLVE 1 |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase III |
| Variant Requirements | Yes |
| Sponsors | Stichting Hemato-Oncologie voor Volwassenen Nederland |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | SWE | NOR | NLD | LTU | ITA | IRL | GBR | FRA | FIN | EST | ESP | DNK | DEU | CHE | BEL | AUT |
CKB BOOST